Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of Continuous Infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 Hours in Term Pregnant, Nulliparous Women to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of Continuous Infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 Hours in Term Pregnant, Nulliparous Women to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Tafoxiparin (Primary)
  • Indications Labour induction
  • Focus Therapeutic Use
  • Sponsors Dilafor
  • Most Recent Events

    • 24 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 27 Sep 2016 According to Dilafor media release, this trial is planned to start before the year end 2016.
    • 27 Sep 2016 Planned initiation date changed from 1 Jul 2015 to 1 Dec 2016, as per Dilafor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top